Current issues in dendritic cell cancer immunotherapy

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 1, 2002, Pages 54-63

  López, José A ^a   Hart, Derek N J ^a  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Cancer; Clinical trials; Dendritic cells; Immunotherapy; Vaccine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; MELAN A; RECOMBINANT ANTIGEN; TUMOR ANTIGEN; VIRUS VECTOR;

ARTICLE; BLOOD TOXICITY; CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LIVER TOXICITY; MALIGNANT TRANSFORMATION; NEPHROTOXICITY; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; VITILIGO;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD34; ANTIGENS, NEOPLASM; BLOOD CELLS; CELL MOVEMENT; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MONOCYTES; NEOPLASMS;

EID: 0036085324     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Proliferating dendritic cell progenitors in human blood
2. Danger signals: SOS to the immune system
3. Natural adjuvants: Endogenous activators of dendritic cells
4. The role of dendritic cells in the innate immune system
5. Surgical and physical stress increase circulating blood dendritic cell counts independently of monocyte counts
6. Minimal recruitment and activation of dendritic cells within renal cell carcinoma
7. Phenotypic characterization of the dendritic cell infiltrate in prostate cancer
8. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated
9. Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD-83 Expression
10. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
11. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients
12. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth interleukin-10
13. Clinical significance of defective dendritic cell differentiation in cancer
14. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
15. Immunobiology of dendritic cells
16. Dendritic cells: Unique leukocyte populations which control the primary immune response
17. Dendritic cells and their emerging clinical applications
18. Growth factors, cytokines and dendritic cell development
19. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood
20. Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma
21. Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells
22. 7th leucocyte differentiation antigen workshop DC section summary
23. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells
24. Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines
25. Dendritic cells as vectors for therapy
26. Simplified method to generate large quantities of dendritic cells suitable for clinical applications
27. Regulatory activity of autocrine IL-10 on dendritic cell functions
28. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
29. Isolation of human blood dendritic cells by Nycodenz discontinuous gradient centrifugation
30. Dendritic cells in cancer immunotherapy
31. Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56
32. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
33. In vivo generation of human dendritic cell subsets by Flt3 ligand
34. Growth factors, cytokines and dendritic cell development
35. Dendritic cells: On the move from bench to bedside
36. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100
37. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination
38. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals
39. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
40. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
41. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity
42. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
43. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
44. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
45. Sensing pathogens and tuning immune responses
46. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes
47. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
48. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood
49. Human CD25(+)CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function
50. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
51. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
52. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells
53. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12
54. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway
55. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
56. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
57. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli
58. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
59. Dendritic cells injected via different routes induce immunity in cancer patients
60. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
61. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines
62. Migration of human dendritic cells after injection in patients with metastatic malignancies
63. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
64. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
65. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide
66. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
67. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
68. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
69. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine
70. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
71. Transient expansion of peptide-specific lymphocytes producing IFNγ after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors
72. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
73. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma
74. Dendritic cell-based treatment of cancer: Closing in on a cellular therapy
75. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
76. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
77. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
78. Dendritic cells in cancer immunotherapy
79. The risk of autoimmunity associated with tumor immunotherapy
80. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
81. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma
82. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
83. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
84. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation
85. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells
86. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma
87. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
88. Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: Report of a case
89. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
90. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
91. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
92. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma
93. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
94. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
95. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
96. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
97. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells
98. Dendritic cell vaccination with mage peptide is a novel therapeutic approach for gastrointestinal carcinomas
99. Treatment of solid tumors in children with tumor-lysate-pulsed dendritic cells
100. Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma